News Center
-
Breaking Through in International Multicenter Clinical Mutual Recognition, "R&D Without Borders · Sino Biopharmaceutical Sets Sail" International Biopharmaceutical Innovation and Development Forum Held in Shanghai
On June 6, the "R&D Without Borders · Sino Biopharmaceutical Sets Sail" International Biopharmaceutical Innovation and Development Forum was held at the Chia Tai Tianqing Global R&D Headquarters in Minhang District, Shanghai.View -
Sino Biopharmaceutical Wins Three Major Honors in Sustainability from S&P Global
Recently, S&P Global, an internationally authoritative sustainability assessment agency, held the launch ceremony for "The Sustainability Yearbook" (China Edition) 2026 in Shanghai.View -
100 Million Yuan Donation! Chia Tai Tianqing Partners with China Science and Technology Development Foundation to Co-create a Biopharmaceutical Innovation Ecosystem
On May 22, Chia Tai Tianqing Pharmaceutical Group, a core enterprise of Sino Biopharmaceutical (1177.HK), donated 100 million yuan to the China Science and Technology Development Foundation. This move actively implements the national "15th Five-Year Plan" strategic layout, helps build the biopharmaceutical industry into a national emerging pillar industry, and empowers the nation's high-level scientific and technological self-reliance with concrete actions.View -
"We Cannot Always Be on the Path of Catching Up": Theresa Tse Decodes the Blue Ocean of Innovation for Sino Biopharmaceutical at CICC Healthcare Investment Conference
On May 14, the 6th CICC Healthcare Industry Summit 2026 was held in Shanghai. Theresa Tse, Chairwoman of the Board of Sino Biopharmaceutical (1177.HK), attended and delivered a speech, providing a clear answer for achieving a global breakthrough through a differentiated M&A strategy for local Chinese pharmaceutical companies, combined with a leading advantage across the entire value chain.View
Science for a healthier world
